Mumbai (Maharashtra) [India], May 19: Q-Line Biotech Limited is an Indian in-vitro diagnostics (IVD) and healthcare solutions company engaged in manufacturing and supplying diagnostic reagents, rapid test kits, molecular diagnostics, pathology equipment, and related consumables used by hospitals, laboratories, and healthcare institutions across India. Proposes to open its Initial Public Offering on May 21, 2026, aiming to raise ₹ 214.48 Crores (at upper price band) with shares to be listed on the NSE Emerge platform.
QIB Anchor Portion – Up to 17,81,200 Equity Shares
Net QIB – Up to 11,88,000 Equity Shares
Non-Institutional Investors – Not Less Than 8,91,600 Equity Shares
Individual Investors – Not Less Than 20,79,200 Equity Shares
Market Maker – 3,13,200 Equity Shares
The net proceeds from the IPO will be utilized to meet working capital, repayment of certain borrowings, and the general corporate purposes. The anchor bidding is on Wednesday, May 20, 2026. The issue will open on Thursday, May 21, 2026, and will close on Monday, May 25, 2026.
The Book Running Lead Manager to the Issue is HEM Securities Limited & Share India Capital Services Private Limited, and the Registrar is Purva Sharegistry (India) Private Limited.
About Q-Line Biotech Limited:
Q-Line Biotech Limited is engaged in the business of developing, manufacturing, and marketing a diverse range of reagents (including kits and POC devices) & consumables, and manufacturing, importing, distributing/supplying diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities, and quality assurance. The core segments of operations of the company in the IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and Others (POC Devices & Rapid Tests).
The key manufacturing segments include indigenous manufacturing of reagents and supplying/manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further, during the Covid-19 pandemic, the company diversified its focus and, with the technical collaboration of third-party institutes and through its own R&D team, developed a range of Covid testing kits, viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits, etc.
In FY25, the Company achieved a Revenue of ₹ 31,378.04 Lakhs, EBITDA of ₹ 7,132.12 Lakhs & PAT of ₹2,813.09Lakhs.
For the nine-month period ended December 2025, the Company achieved a Revenue of ₹ 23,242.03 Lakh, EBITDA of ₹6,422.98 Lakh & PAT of ₹3,869.39 Lakh.
If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.
rss_feed
Disclaimer:This content is sourced from syndicated feeds, PR agencies, or brand submissions. Views expressed are those of the respective authors, and we do not independently verify them..
PNN
(This story has been published from a syndicated feed, agency source, or press release. NewsWaala Team may not have edited or verified the content independently.)
